PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67556-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)67556-0/fulltext
Title :
PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67556-0&doi=10.1016/S1098-3015(10)67556-0
First page :
Section Title :
Open access? :
No
Section Order :
130